Key result
Olaratumab in combination with doxorubicin has been contingently approved for adult patients with advanced soft tissue sarcoma, with a tolerable safety profile mimicking doxorubicin monotherapy.
Why the study?
Does olaratumab combined with doxorubicin improve progression-free and overall survival in adult patients with advanced soft tissue sarcoma?
Does olaratumab combined with doxorubicin improve progression-free and overall survival in adult patients with advanced soft tissue sarcoma?
Olaratumab combined with doxorubicin is a contingently approved therapy for advanced soft tissue sarcoma that improves survival with a tolerable safety profile.
Answers are grounded in this paper and cite their sources.
Olaratumab-doxorubicin shows tolerable safety in advanced STS; leaves open optimal role until confirmatory phase 3 survival data mature.
Olaratumab, the first-in-class anti-PDGFRα monoclonal antibody, has been contingently approved in combination with doxorubicin to treat adult patients with advanced soft tissue sarcoma for improving progression-free and overall survival. Olaratumab-doxorubicin combination has tolerable safety profile, which mimics that of doxorubicin monotherapy, with the exception of infusion-related reactions. Survival data of an ongoing confirmatory phase 3 trial are forthcoming to ascertain the optimal role of this product in the management algorithm of advanced soft tissue sarcoma. Active research is ongoing to identify biomarkers predictive of clinical benefit to olaratumab, to expand its utility to the pediatric population, and to explore its safety and efficacy in combination with other active regimens.
No takes yet. Share an insight, caveat, or question.
Zobniw et al. (2018) conducted a review in Advanced soft tissue sarcoma. Olaratumab in combination with doxorubicin vs. Doxorubicin monotherapy was evaluated on Progression-free and overall survival. Olaratumab in combination with doxorubicin has been contingently approved for adult patients with advanced soft tissue sarcoma, with a tolerable safety profile mimicking doxorubicin monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: